Comparative Pharmacology
Head-to-head clinical analysis: ANKTIVA versus TERIFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANKTIVA versus TERIFLUNOMIDE.
ANKTIVA vs TERIFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANKTIVA is a live attenuated, nonpathogenic recombinant strain of Vibrio cholerae O1 (CVD 103-HgR) that colonizes the intestinal mucosa and elicits protective mucosal and systemic immune responses against V. cholerae, including production of vibriocidal and antitoxin antibodies.
Teriflunomide inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis, thereby reducing proliferation of activated T and B lymphocytes.
Intravesical instillation of 300 mg (25 mL) once weekly for 6 weeks, followed by maintenance therapy of 300 mg once monthly for 6 or 12 months.
7 mg orally once daily with or without food.
None Documented
None Documented
Clinical Note
moderateTeriflunomide + Gatifloxacin
"Teriflunomide may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateTeriflunomide + Rosoxacin
"Teriflunomide may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateTeriflunomide + Trovafloxacin
"Teriflunomide may increase the neuroexcitatory activities of Trovafloxacin."
Clinical Note
moderateTeriflunomide + Nalidixic acid
Terminal elimination half-life: 12-15 hours; clinically, steady-state reached after 2-3 days
Terminal half-life approximately 18-19 days (range 10-30 days) due to enterohepatic recirculation. Clinical context: Requires prolonged elimination (up to 2 years to reach undetectable levels) due to slow clearance; accelerated elimination with cholestyramine or activated charcoal may be needed for toxicity.
Renal: ~70% unchanged; fecal: ~30% as metabolites
Primarily biliary/fecal (approximately 60% unchanged drug and metabolites in feces, 23% in urine). Renal elimination of unchanged drug is minimal (<0.5%). Enterohepatic recycling contributes to long half-life.
Category C
Category C
Immunomodulator
Immunomodulator
"Teriflunomide may increase the neuroexcitatory activities of Nalidixic acid."